Kingmed Diagnostics is a third-party medical inspection service provider.
Kingmed Diagnostics, established in 1994, is a third-party medical inspection and pathological diagnosis service provider, mainly engaging in third-party medical assessment and pathological diagnosis business and providing leading medical diagnosis information integration services and and pathological diagnosis outsourcing services for medical institutions at all levels across the country. Founded by Guangzhou Medical University, it went public in September 2017. Its main shareholder is Liang Yaoming, and peer companies are Transtek Medical Electronics and Inkon Life Technology.
F-star to be acquired by China biopharmaceutical with USD 161million
"Delisting warning" of Whitson pharmaceuticals on the New York Stock Exchange
Tsingke Biotechnology: More Opportunities in the International Market of Gene Synthesis
‘Globalization is the only way to the development of the industry. It is more conducive to the rapid progress of the industry for domestic enterprises to compete with well-known overseas enterprises.’
Jan 30, 2023 02:13 PM
Herui gene launched the early screening product "quansining" for multiple cancer types, covering six high-risk cancer types
East China medicine "liraglutide" goes to sea
2022 China AI Health 30 Report
ResearchConsumer Staples, Healthcare, Technology
WIA2020 | Rising Tech Stars 2020: Global & China's 100
Nearly half of the equity of two subsidiaries of Tongrentang was transferred to Tongrentang medical care
Baiyunshan: suspension of the spin off of Guangzhou Pharmaceutical for overseas listing
Germany Merck "cetuximab" new indications for head and neck squamous cell carcinoma approved in China
Ningxia building materials: net profit in the first quarter increased by 741% year-on-year
10 billion private equity Xitai investment's products suffered a large loss and hit the early warning line
Jinyu medicine: we are actively cooperating in the investigation of Jinyu incident in Zhengzhou
Zhong Nanshan: Omicron made many countries understand that China's prevention and control is right
Dynamic Biosystems Snags Nearly CNY 100 Mn in Series A+
Dynamic Biosystems is a single cell and space multi-omics technology platform enterprise. The company focuses on exploring the huge potential in the fields of precision medicine of tumor, eugenics and fertility, and drug discovery, and is committed to promoting precision medicine to the era of single cell and space omics, helping life science and clinical medicine.
Feb 06, 2023 07:25 PM
Opportunities and Challenges Hidden in the CGT Industry in China
CGT (Cell and Gene Therapy) is a sector with high growth potential. CAR-T, as one of the main CGT currently, presents great value for both doctors and patients. This article showcases the industry pain points and opportunities faced in the CAR-T sub-sector.
Jan 17, 2023 05:48 PM
Gilid signed an agreement with science and technology to deepen strategic cooperation in the areas of chronic hepatitis B, hepatitis C and HIV infection.
Gu Gang of HNA Group: 4 bankruptcy meeting processes of RMB 2 trillion declaration of creditor's rights have been successfully completed, waiting for the ruling
Zhongyuan expressway: the net profit in the first half of the year was 642 million yuan, turning losses into profits year-on-year
Back to Hong Kong, Chinese concept stocks rose collectively, and Wanguo data rose 17.5%